Related references
Note: Only part of the references are listed.Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
Teresa E. Peterson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy
Harold F. Dvorak
CANCER JOURNAL (2015)
The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment
W. Hans Meisen et al.
CLINICAL CANCER RESEARCH (2015)
Lessons From Anti-Vascular Endothelial Growth Factor and Anti-Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma
Christine Lu-Emerson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The interaction of anticancer therapies with tumor-associated macrophages
Alberto Mantovani et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
LB-05PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIAL
W. Wick et al.
NEURO-ONCOLOGY (2015)
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Sara M. Tolaney et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Targeting Vascular Pericytes in Hypoxic Tumors Increases Lung Metastasis via Angiopoietin-2
Doruk Keskin et al.
CELL REPORTS (2015)
Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+ T-cell responses and immune memory
Junjie Wu et al.
ONCOIMMUNOLOGY (2015)
Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack
Italia Grenga et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data
Patrick A. Ott et al.
FRONTIERS IN ONCOLOGY (2015)
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
Tumor-Associated Macrophages: From Mechanisms to Therapy
Roy Noy et al.
IMMUNITY (2014)
Vessel calibre-a potential MRI biomarker of tumour response in clinical trials
Kyrre E. Emblem et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes
Konrad Gabrusiewicz et al.
ONCOTARGET (2014)
Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
Nicolo Rigamonti et al.
CELL REPORTS (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition
Christopher Daly et al.
CANCER RESEARCH (2013)
Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
Yvonne Kienast et al.
CLINICAL CANCER RESEARCH (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy
Kyrre E. Emblem et al.
NATURE MEDICINE (2013)
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail et al.
NATURE MEDICINE (2013)
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
Christine Lu-Emerson et al.
NEURO-ONCOLOGY (2013)
NCBI GEO: archive for functional genomics data sets-update
Tanya Barrett et al.
NUCLEIC ACIDS RESEARCH (2013)
A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors
Markus Thomas et al.
PLOS ONE (2013)
Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target
Basel Sitohy et al.
CANCER RESEARCH (2012)
Anastomosis of endothelial sprouts forms new vessels in a tissue analogue of angiogenesis
Jonathan W. Song et al.
INTEGRATIVE BIOLOGY (2012)
Macrophage plasticity and polarization: in vivo veritas
Antonio Sica et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
The molecular profile of microglia under the influence of glioma
Wei Li et al.
NEURO-ONCOLOGY (2012)
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases
David P. Kodack et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Microglia/Macrophages Promote Glioma Progression
Haiyan Zhai et al.
GLIA (2011)
Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion
Seth B. Coffelt et al.
JOURNAL OF IMMUNOLOGY (2011)
Molecular mechanisms and clinical applications of angiogenesis
Peter Carmeliet et al.
NATURE (2011)
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Peter Carmeliet et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence
Wanyu L. Lambiv et al.
NEURO-ONCOLOGY (2011)
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
Wolfgang Schaefer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Fluid forces control endothelial sprouting
Jonathan W. Song et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Angiopoietin-2 Regulates Gene Expression in TIE2-Expressing Monocytes and Augments Their Inherent Proangiogenic Functions
Seth B. Coffelt et al.
CANCER RESEARCH (2010)
Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth
Hiroya Hashizume et al.
CANCER RESEARCH (2010)
Angiopoietin-2 Interferes with Anti-VEGFR2-Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas
Sung-Suk Chae et al.
CLINICAL CANCER RESEARCH (2010)
A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models
Jeffrey L. Brown et al.
MOLECULAR CANCER THERAPEUTICS (2010)
A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood resident monocytes, and embryonic macrophages suggests common functions and developmental relationships
Ferdinando Pucci et al.
BLOOD (2009)
Human Glioblastoma-Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus Vectors
Hiroaki Wakimoto et al.
CANCER RESEARCH (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo
Bakhos A. Tannous
NATURE PROTOCOLS (2009)
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system
Hellmut G. Augustin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
Increased number of microglia in the brain of severe combined immunodeficient (SCID) mice
Dietrich E. Lorke et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2008)
Stem cell-related Self-Renewal signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
Anastasia Murat et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Astrocytic regulation of human monocytic/microglial activation
Alex M. Kostianovsky et al.
JOURNAL OF IMMUNOLOGY (2008)
A secreted luciferase for ex vivo monitoring of in vivo processes
Thomas Wurdinger et al.
NATURE METHODS (2008)
Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer
Mary Anna Venneri et al.
BLOOD (2007)
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF
WC Liang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Tie2 identifies a hematopoietic monocytes required for tumor lineage of proangiogenic vessel formation and a mesenchymal population of pericyte progenitors
M De Palma et al.
CANCER CELL (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
